ismaell masalha

Dr. ismaell masalha

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Walid ShalataWalid Shalata
Walid Shalata
AAAmjad Abu-Salman
Amjad Abu-Salman
RSRachel Steckbeck
Rachel Steckbeck
BJBinil Mathew Jacob
Binil Mathew Jacob
ismaell masalhaismaell masalha
ismaell masalha
AYAlexander Yakobson
Alexander Yakobson
Immune checkpoint inhibitors are immune stimulatory drugs used to treat many types of cancer. These drugs are antibodies against inhibitory proteins, such as CTLA-4 and PD-1/PD-L1, that are expressed on immune cells. When bound, they allow for increased stimulation of T cells to fight tumor cells. However, immune checkpoint inhibitors have several immune-related adverse effects. Many cases have come to light recently of cardiotoxicity as a result of treatment with these drugs. Cardiotoxicity from immune checkpoint inhibitors is unique due to its rarity and high mortality rate. Patients with this toxicity may present with myocarditis, pericarditis, Takotsubo cardiomyopathy, conduction disorders, and others within just a few weeks of starting immune checkpoint inhibitors. We present here a review of the current research on immune checkpoint inhibitors, their associated cardiotoxicities, the timing of presentation of these conditions, lab tests and histology for each condition, and finally the treatment of patients with cardiotoxicity. We observe a positive skew in the onset of presentation, which is significant for the treating physician.

20 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Walid ShalataWalid Shalata
Walid Shalata
MImuhammed iraqi
muhammed iraqi
BBBaisali Bhattacharya
Baisali Bhattacharya
VFVered Fuchs
Vered Fuchs
Laila C. RoismanLaila C. Roisman
Laila C. Roisman
NPNir Peled
Nir Peled
The new era of cancer treatments has made immune checkpoint inhibitors (ICIs) and emerging multikinase inhibitors (TKIs) the standards of care, thus drastically improving patient prognoses. Pembrolizumab is an anti-programmed cell death-1 antibody drug, and lenvatinib is a TKI with preferential antiangiogenic activity. We present, to our knowledge, the first reported series of cases consisting of patients with metastatic non–small cell lung cancer and malignant pleural mesothelioma who were treated with several types of chemotherapy combinations and ICIs followed by disease progression. They were subsequently treated with combined immunotherapy and TKI treatment, resulting in a near complete response within a very short time. Clinical responses were supported by in vitro testing of each patient’s lymphocytic response to pembrolizumab after pre-exposure of target cancer cells to lenvatinib.

20 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ismaell masalhaismaell masalha
ismaell masalha
RZReem Zabit
Reem Zabit
SHSamer Hussany
Samer Hussany
AHAdham Hijab
Adham Hijab
WHWael Hozaeel
Wael Hozaeel
RGRavit Geva
Ravit Geva
Background: Pathological tumor regression is a key prognostic marker in resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma. Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) established the modern treatment backbone, and the recent MATTERHORN trial further intensified this paradigm with the addition of durvalumab. However, a substantial proportion of patients fail to achieve major pathological regression, and the prognostic magnitude of poor response in the FLOT era has not been systematically quantified. Methods: We performed a PRISMA 2020–compliant, PROSPERO registered (CRD420251150054) systematic review and meta-analysis. PubMed, Web of Science, Scopus, and Cochrane were searched through September 2025 for studies including patients with resectable gastric/GEJ adenocarcinoma treated with perioperative FLOT followed by curative surgery. Associations between poor pathological response and survival were quantified. Exploratory analyses evaluated completion of postoperative FLOT versus incomplete therapy. Random effects models were applied to pooled hazard ratios (HRs). Results: Twelve studies comprising 4201 resected patients were included in this systematic review; 1817 (43.2%) were classified as poor responders. Poor pathological response was strongly associated with inferior outcomes: pooled HR for overall survival (OS) was 2.73 (95% CI 2.18–3.43; I2=0.0%) and pooled HR for disease-free/recurrence-free survival (DFS/RFS) was 2.68 (95% CI 2.14–3.34; I2=51.2%). Effect direction was consistent across Becker, Mandard, and CAP grading systems. Exploratory analysis of three observational cohorts found an association between completion of postoperative FLOT and improved survival (HR 0.49, 95% CI 0.31–0.79); however, this comparison is inherently confounded by postoperative fitness and treatment selection and should not inform clinical decision-making. Conclusions: Poor pathological response after perioperative FLOT identifies a large, high risk subgroup with approximately threefold inferior survival despite R0 resection. These findings establish contemporary prognostic benchmarks and underscore the absence of prospective evidence guiding postoperative management in poor responders.

19 July 2023 in Life
Verified
Journal Article
Open access
PDF file
Walid ShalataWalid Shalata
Walid Shalata
ismaell masalhaismaell masalha
ismaell masalha
SIShlomo Yaron Ishay
Shlomo Yaron Ishay
ECElena Chernomordikova
Elena Chernomordikova
AJAshraf Abu jama
Ashraf Abu jama
AYAlex Yakobson
Alex Yakobson
In this particular case study, we present a 66-year-old male who was diagnosed with an atrial myxoma eight years after receiving treatment for non-small cell lung cancer. The patient underwent chemo-radiotherapy (mediastinal area) in 2012 to address stage III-A adenocarcinoma of the lung. During follow-up imaging in 2020, a left atrial mass displaying characteristic features of a cardiac myxoma was detected. Upon reviewing a computed tomographic (CT) scan from 2017 within the previously irradiated mediastinal region, the cardiac mass was retrospectively identified. The surgical excision of the cardiac mass was performed, and a subsequent pathological examination confirmed the diagnosis of myxoma. To the best of our knowledge, this is the first reported case of a left atrial myxoma in a patient previously treated for adenocarcinoma of the lung and the first instance of an atrial myxoma occurring in a site that had undergone prior radiation therapy.

18 August 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
ismaell masalhaismaell masalha
ismaell masalha
RZReem Zabit
Reem Zabit
ASAryeh Shalev
Aryeh Shalev
GBGal Ben-Arie
Gal Ben-Arie
Background and Clinical Significance: Zoledronic acid (ZA) is a widely used bisphosphonate for the prevention of skeletal-related events in patients with metastatic bone disease. While it is generally well tolerated, rare immune-mediated complications may be underrecognized. To date, myocarditis has not been reported in association with ZA. Case Presentation: A 35-year-old woman with metastatic pheochromocytoma developed acute, non-exertional chest pain approximately 36 h after receiving her first intravenous ZA infusion. Laboratory testing revealed elevated high-sensitivity troponin T, peaking at 1182 ng/L. Cardiac magnetic resonance imaging (CMR) demonstrated myocardial edema and subepicardial late gadolinium enhancement, consistent with acute myocarditis per the 2018 revised Lake Louise criteria. An extensive diagnostic workup excluded infectious, autoimmune, and ischemic causes. Symptoms and troponin levels improved following ZA discontinuation and supportive care. In the absence of alternative etiologies, and given the close temporal association with ZA administration, the diagnosis of presumed ZA-associated myocarditis was supported by clinical presentation, biochemical markers, and CMR findings, recognizing that histopathological confirmation is rarely pursued in clinically stable patients. Conclusions: To our knowledge, this is the first reported case of presumed zoledronic acid–associated myocarditis confirmed by cardiac MRI. This report highlights the diagnostic utility of CMR in suspected drug-related cardiac inflammation and the importance of considering myocarditis in patients presenting with unexplained chest pain following ZA infusion, particularly when other causes have been excluded.

24 May 2026 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
ismaell masalhaismaell masalha
ismaell masalha